1,976 results on '"Hillege, Hans"'
Search Results
302. PS4 - 23. Bilirubin and risk of type 2 diabetes: a mendelian randomization approach
- Author
-
Abbasi, Ali, Corpeleijn, Eva, Gansevoort, Ron T., Gans, Rijk O.B., Hillege, Hans L., van der Harst, Pim, Stolk, Ronald P., Navis, Gerjan, and Bakker, Stephan J.L.
- Published
- 2012
- Full Text
- View/download PDF
303. Age dependent associations of risk factors with heart failure: pooled population based cohort study.
- Author
-
Tromp, Jasper, Paniagua, Samantha M. A., Lau, Emily S., Allen, Norrina B., Blaha, Michael J., Gansevoort, Ron T., Hillege, Hans L., Lee, Douglas E., Levy, Daniel, Ramachandran, Vasan S., van der Harst, Pim, van Gilst, Wiek H., Larson, Martin G., Shah, Sanjiv J., de Boer, Rudolf A., Lam, Carolyn S. P., and Ho, Jennifer E.
- Subjects
HEART failure risk factors ,HYPERTENSION ,OBESITY ,VENTRICULAR ejection fraction ,CONFIDENCE intervals ,SCIENTIFIC observation ,AGE distribution ,DIABETES ,MYOCARDIAL infarction ,POPULATION health ,SMOKING ,LONGITUDINAL method - Published
- 2021
- Full Text
- View/download PDF
304. Measurement of coronary calcium scores or exercise testing as initial screening tool in asymptomatic subjects with ST-T changes on the resting ECG: an evaluation study
- Author
-
de Jong Paul E, Willems Tineke P, Hillege Hans L, Vliegenthart Rozemarijn, Slart Riemer HJA, Tio René A, Kors Jan A, Dikkers Riksta, Geluk Christiane A, van Gilst Wiek H, Oudkerk Matthijs, and Zijlstra Felix
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Asymptomatic subjects at intermediate coronary risk may need diagnostic testing for risk stratification. Both measurement of coronary calcium scores and exercise testing are well established tests for this purpose. However, it is not clear which test should be preferred as initial diagnostic test. We evaluated the prevalence of documented coronary artery disease (CAD) according to calcium scores and exercise test results. Methods Asymptomatic subjects with ST-T changes on a rest ECG were selected from the population based PREVEND cohort study and underwent measurement of calcium scores by electron beam tomography and exercise testing. With calcium scores ≥10 or a positive exercise test, myocardial perfusion imaging (MPS) or coronary angiography (CAG) was recommended. The primary endpoint was documented obstructive CAD (≥50% stenosis). Results Of 153 subjects included, 149 subjects completed the study protocol. Calcium scores ≥400, 100–399, 10–99 and Conclusion Measurement of coronary calcium scores is an appropriate initial non-invasive test in asymptomatic subjects at increased coronary risk.
- Published
- 2007
- Full Text
- View/download PDF
305. Predictors of mortality in patients with sustained ventricular tachycardias or ventricular fibrillation and depressed left ventricular function: Importance of β-blockade
- Author
-
Szabó, Balázs M., Crijns, Harry J. G. M., Wiesfeld, Ans C. P., van Veldhuisen, Dirk J., Hillege, Hans L., and Lie, K. I.
- Published
- 1995
306. Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma : a feasibility study
- Author
-
Makady, Amr, Kalf, Rachel R. J., Ryll, Bettina, Spurrier, Gilliosa, de Boer, Anthonius, Hillege, Hans, Klungel, Olaf H., Goettsch, Wim, Makady, Amr, Kalf, Rachel R. J., Ryll, Bettina, Spurrier, Gilliosa, de Boer, Anthonius, Hillege, Hans, Klungel, Olaf H., and Goettsch, Wim
- Abstract
Purpose: Development of innovative drugs for melanoma is occurring rapidly. Incremental gains in overall survival amongst innovative products may be difficult to measure in clinical trials, and their use may be associated with increased toxicity profiles. Therefore, HTA agencies increasingly require information on HRQoL for the assessment of such drugs. This study explored the feasibility of social media to assess patient perspectives on HRQoL in melanoma, and whether current cancer- and melanoma-specific HRQoL questionnaires represent these perspectives. Methods: A survey was distributed on the social media channels of Melanoma Patient Network Europe to assess melanoma patients' perspectives regarding HRQoL. Two researchers independently conducted content analysis to identify key themes, which were subsequently compared to questions from one current cancer-specific and two melanoma-specific HRQoL questionnaires (i.e. EORTC QLQ-C30, EORTC QLQ-MEL38, FACT-M). Results: In total, 72 patients and 17 carers completed the survey. Patients indicated that family, having a normal life, and enjoying life were the three most important aspects of HRQoL for them. Carers indicated that being capable, having manageable adverse events, and being pain-free were the three most important aspects of HRQoL for patients. Respondents seem to find some questions from HRQoL questionnaires relevant (e.g. Have you felt able to carry on with things as normal?') and others less relevant (e.g. Have you had swelling near your melanoma site?'). Additionally, wording may differ between patients and HRQoL questionnaires, whereby patients generally use a more positive tone. Conclusions: Social media may provide a valuable tool in assessing patient perspectives regarding HRQoL. However, differences seem to emerge between patient and carer perspectives. Additionally, patient perspectives did not seem to fully correlate to questions posed in cancer- (i.e. EORTC QLQ-C30) and melanoma-specific (i.e. EORTC
- Published
- 2018
- Full Text
- View/download PDF
307. Using social media to collect patient perspectives on quality of life : A feasibility study
- Author
-
Makady, Amr, Kalf, Rachel, Ryll, Bettina, Spurrier, Gilliosa, de Boer, Anthonius, Hillege, Hans, Klungel, Olaf, Goettsch, Wim, Makady, Amr, Kalf, Rachel, Ryll, Bettina, Spurrier, Gilliosa, de Boer, Anthonius, Hillege, Hans, Klungel, Olaf, and Goettsch, Wim
- Published
- 2018
- Full Text
- View/download PDF
308. The dynamics of self-care in the course of heart failure management: data from the IN TOUCH study
- Author
-
Lycholip, Edita, Aamodt, Ina Thon, Lie, Irene, Simbelyte, Toma, Puronaite, Roma, Hillege, Hans, de Vries, Arjen, Kraai, Imke, Strömberg, Anna, Jaarsma, Tiny, Celutkiene, Jelena, Lycholip, Edita, Aamodt, Ina Thon, Lie, Irene, Simbelyte, Toma, Puronaite, Roma, Hillege, Hans, de Vries, Arjen, Kraai, Imke, Strömberg, Anna, Jaarsma, Tiny, and Celutkiene, Jelena
- Abstract
Introduction: Self-care is an important patient-reported outcome (PRO) for heart failure (HF) patients, which might be affected by disease management and/or telemonitoring (TM). The number of studies reporting the influence of TM on self-care is limited. Aims: This study aimed: to assess whether TM, in addition to information-and-communication-technology (ICT)-guided disease management system (ICT-guided DMS), affects self-care behavior; to evaluate the dynamics of self-care during the study; to investigate factors contributing to self-care changes; and to identify a patient profile that predisposes the patient to improvement in self-care. Methods: In the INnovative ICT-guided-DMS combined with Telemonitoring in OUtpatient clinics for Chronic HF patients (IN TOUCH) study, 177 patients were randomized to either ICT-guided DMS or TM+ICT-guided DMS, with a follow-up of 9 months. The current analysis included 118 participants (mean age: 69 +/- 11.5 years; 70% male) who filled the following PRO instruments: the nine-item European Heart Failure Self-care Behaviour scale (EHFScBs), Hospital Anxiety and Depression scale (HADs), and Minnesota Living with HF Questionnaire (MLHFQ). Results: The baseline level of self-care was better in the TM+ICT-guided-DMS group (n=58) compared to ICT-guided-DMS group (n=60, p=0.023). Self-care behavior improved in the ICT-guided-DMS group (p amp;lt; 0.01) but not in the TM+ICT-guided-DMS group. Factors associated with self-care worsening were as follows: higher physical subscale of MLHFQ (per 10 points, p amp;lt; 0.05), lower left ventricular ejection fraction (LVEF) (per 5%, p amp;lt; 0.05), lower New York Heart Association (NYHA) class (class III vs class II, p amp;lt; 0.05). The subgroups of patients who had an initial EHFScBs total score amp;gt; 28, or from 17 to 28 with concomitant HADs depression subscale (HADs_D) score amp;lt;= 8, demonstrated the greatest potential to improve self-care during the study. Conclusion: TM did not have an, Funding Agencies|Dutch Ministry of Health, Department of Pharmaceutical Affairs and Medical Technology (GMT); NordForsks "Nordic Programme on Health and Welfare" [76015]
- Published
- 2018
- Full Text
- View/download PDF
309. Normal values of corrected heart-rate variability in 10-second electrocardiograms for all ages
- Author
-
van den Berg, Marten E., Rijnbeek, Peter R., Niemeijer, Maartje N., Hofman, Albert, Herpen, Gerard van, Bots, Michiel L., Hillege, Hans, Swenne, Cees A., Eijgelsheim, Mark, Stricker, Bruno H., Kors, Jan A., van den Berg, Marten E., Rijnbeek, Peter R., Niemeijer, Maartje N., Hofman, Albert, Herpen, Gerard van, Bots, Michiel L., Hillege, Hans, Swenne, Cees A., Eijgelsheim, Mark, Stricker, Bruno H., and Kors, Jan A.
- Published
- 2018
310. Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: A feasibility study 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis
- Author
-
Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Makady, Amr, Kalf, Rachel R.J., Ryll, Bettina, Spurrier, Gilliosa, De Boer, Anthonius, Hillege, Hans, Klungel, Olaf H., Goettsch, Wim, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Makady, Amr, Kalf, Rachel R.J., Ryll, Bettina, Spurrier, Gilliosa, De Boer, Anthonius, Hillege, Hans, Klungel, Olaf H., and Goettsch, Wim
- Published
- 2018
311. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
- Author
-
Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Makady, Amr, van Veelen, Ard, Jonsson, Páll, Moseley, Owen, d'Andon, Anne, de Boer, Anthonius, Hillege, Hans, Klungel, Olaf, Goettsch, Wim, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Makady, Amr, van Veelen, Ard, Jonsson, Páll, Moseley, Owen, d'Andon, Anne, de Boer, Anthonius, Hillege, Hans, Klungel, Olaf, and Goettsch, Wim
- Published
- 2018
312. Using social media to collect patient perspectives on quality of life: A feasibility study
- Author
-
Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Makady, Amr, Kalf, Rachel, Ryll, Bettina, Spurrier, Gilliosa, De Boer, Anthonius, Hillege, Hans, Klungel, Olaf, Goettsch, Wim, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Makady, Amr, Kalf, Rachel, Ryll, Bettina, Spurrier, Gilliosa, De Boer, Anthonius, Hillege, Hans, Klungel, Olaf, and Goettsch, Wim
- Published
- 2018
313. The dynamics of self-care in the course of heart failure management: data from the IN TOUCH study
- Author
-
Lycholip,Edita, Thon Aamodt,Ina, Lie,Irene, Å imbelytÄ,Toma, PuronaitÄ,Roma, Hillege,Hans, de Vries,Arjen, Kraai,Imke, Stromberg,Anna, Jaarsma,Tiny, ÄelutkienÄ,Jelena, Lycholip,Edita, Thon Aamodt,Ina, Lie,Irene, Å imbelytÄ,Toma, PuronaitÄ,Roma, Hillege,Hans, de Vries,Arjen, Kraai,Imke, Stromberg,Anna, Jaarsma,Tiny, and ÄelutkienÄ,Jelena
- Abstract
Edita Lycholip,1,2 Ina Thon Aamodt,3,4 Irene Lie,3 Toma ŠimbelytÄ,5 Roma PuronaitÄ,2,6,7 Hans Hillege,8 Arjen de Vries,8 Imke Kraai,9 Anna Stromberg,10 Tiny Jaarsma,11 Jelena ÄelutkienÄ1,2 1Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; 2Center of Cardiology and Angiology, Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania; 3Centre for Patient-Centered Heart and Lung Research, Department of Cardiothoracic Surgery, Division of Cardiovascular and Pulmonary Diseases, Oslo University Hospital, Oslo, Norway; 4Department of Nursing Science, Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway; 5Clinic of Internal Medicine, Centre of Family and Internal Medicine, Vilnius University Santaros Clinics, Vilnius University, Vilnius, Lithuania; 6Centre of Informatics and Development, Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania; 7Institute of Mathematics and Informatics, Vilnius University, Vilnius, Lithuania; 8Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 9PRA Health Sciences – Early Development Services, Groningen, the Netherlands; 10Department of Medical and Health Sciences, Linkoping University, Linkoping, Sweden; 11Department of Social and Welfare Studies, Linkoping University, Norrkoping, Sweden Introduction: Self-care is an important patient-reported outcome (PRO) for heart failure (HF) patients, which might be affected by disease management and/or telemonitoring (TM). The number of studies reporting the influence of TM on self-care is limited.Aims: This study aimed: to assess whether TM, in addition to information-and-communication-technology (ICT)-guided disease management system (ICT-guided DMS), affects self-care behavior; to evaluate the dynamics of self-care during the study; to investigate factors contributing to self-care changes; and to identify a patient pr
- Published
- 2018
314. Normal values of corrected heart-rate variability in 10-second electrocardiograms for all ages
- Author
-
Cardiovasculaire Epi Team 5, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, van den Berg, Marten E., Rijnbeek, Peter R., Niemeijer, Maartje N., Hofman, Albert, Herpen, Gerard van, Bots, Michiel L., Hillege, Hans, Swenne, Cees A., Eijgelsheim, Mark, Stricker, Bruno H., Kors, Jan A., Cardiovasculaire Epi Team 5, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, van den Berg, Marten E., Rijnbeek, Peter R., Niemeijer, Maartje N., Hofman, Albert, Herpen, Gerard van, Bots, Michiel L., Hillege, Hans, Swenne, Cees A., Eijgelsheim, Mark, Stricker, Bruno H., and Kors, Jan A.
- Published
- 2018
315. A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts.
- Author
-
Chen, Yuntao, Voors, Adriaan A., Jaarsma, Tiny, Lang, Chim C., Sama, Iziah E., Akkerhuis, K. Martijn, Boersma, Eric, Hillege, Hans L., and Postmus, Douwe
- Subjects
HEART failure ,PHENOTYPES ,SYSTOLIC blood pressure ,MORTALITY ,HAZARD function (Statistics) - Abstract
Background: Prognostic models developed in general cohorts with a mixture of heart failure (HF) phenotypes, though more widely applicable, are also likely to yield larger prediction errors in settings where the HF phenotypes have substantially different baseline mortality rates or different predictor-outcome associations. This study sought to use individual participant data meta-analysis to develop an HF phenotype stratified model for predicting 1-year mortality in patients admitted with acute HF.Methods: Four prospective European cohorts were used to develop an HF phenotype stratified model. Cox model with two rounds of backward elimination was used to derive the prognostic index. Weibull model was used to obtain the baseline hazard functions. The internal-external cross-validation (IECV) approach was used to evaluate the generalizability of the developed model in terms of discrimination and calibration.Results: 3577 acute HF patients were included, of which 2368 were classified as having HF with reduced ejection fraction (EF) (HFrEF; EF < 40%), 588 as having HF with midrange EF (HFmrEF; EF 40-49%), and 621 as having HF with preserved EF (HFpEF; EF ≥ 50%). A total of 11 readily available variables built up the prognostic index. For four of these predictor variables, namely systolic blood pressure, serum creatinine, myocardial infarction, and diabetes, the effect differed across the three HF phenotypes. With a weighted IECV-adjusted AUC of 0.79 (0.74-0.83) for HFrEF, 0.74 (0.70-0.79) for HFmrEF, and 0.74 (0.71-0.77) for HFpEF, the model showed excellent discrimination. Moreover, there was a good agreement between the average observed and predicted 1-year mortality risks, especially after recalibration of the baseline mortality risks.Conclusions: Our HF phenotype stratified model showed excellent generalizability across four European cohorts and may provide a useful tool in HF phenotype-specific clinical decision-making. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
316. The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach.
- Author
-
Hoes, Martijn F., Tromp, Jasper, Ouwerkerk, Wouter, Bomer, Nils, Oberdorf‐Maass, Silke U., Samani, Nilesh J., Ng, Leong L., Lang, Chim C., Harst, Pim, Hillege, Hans, Anker, Stefan D., Metra, Marco, Veldhuisen, Dirk J., Voors, Adriaan A., and Meer, Peter
- Subjects
CATHEPSIN D ,BRAIN natriuretic factor ,HEART failure ,PATHOLOGICAL physiology ,TREATMENT effectiveness ,KIDNEY failure - Abstract
Aims: Cathepsin D is a ubiquitous lysosomal protease that is primarily secreted due to oxidative stress. The role of circulating cathepsin D in heart failure (HF) is unknown. The aim of this study is to determine the association between circulating cathepsin D levels and clinical outcomes in patients with HF and to investigate the biological settings that induce the release of cathepsin D in HF. Methods and results: Cathepsin D levels were studied in 2174 patients with HF from the BIOSTAT‐CHF index study. Results were validated in 1700 HF patients from the BIOSTAT‐CHF validation cohort. The primary combined outcome was all‐cause mortality and/or HF hospitalizations. Human pluripotent stem cell‐derived cardiomyocytes were subjected to hypoxic, pro‐inflammatory signalling and stretch conditions. Additionally, cathepsin D expression was inhibited by targeted short hairpin RNAs (shRNA). Higher levels of cathepsin D were independently associated with diabetes mellitus, renal failure and higher levels of interleukin‐6 and N‐terminal pro‐B‐type natriuretic peptide (P < 0.001 for all). Cathepsin D levels were independently associated with the primary combined outcome [hazard ratio (HR) per standard deviation (SD): 1.12; 95% confidence interval (CI) 1.02–1.23], which was validated in an independent cohort (HR per SD: 1.23, 95% CI 1.09–1.40). In vitro experiments demonstrated that human stem cell‐derived cardiomyocytes released cathepsin D and troponin T in response to mechanical stretch. ShRNA‐mediated silencing of cathepsin D resulted in increased necrosis, abrogated autophagy, increased stress‐induced metabolism, and increased release of troponin T from human stem cell‐derived cardiomyocytes under stress. Conclusions: Circulating cathepsin D levels are associated with HF severity and poorer outcome, and reduced levels of cathepsin D may have detrimental effects with therapeutic potential in HF. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
317. Prevention of one-year vein-graft occlusion after aortocoronary- bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants.
- Author
-
van der Meer, Jan, Hillege, Hans L, Kootstra, Gerrit J, Ascoop, Carl A P L, Pfisterer, Matthias, van Gilst, Wiek H, and Lie, Kong I.
- Published
- 1993
318. Autoperfusion balloon versus stent for acute or threatened closure during percutaneous transluminal coronary angioplasty
- Author
-
Muinck, Ebo D. de, Heijer, Peter den, Dijk, Rene B. van, Crijns, Harry J.G.M., Hillege, Hans J., Twisk, S. Pe, and Lie, Kong I.
- Subjects
Transluminal angioplasty -- Methods ,Stent (Surgery) -- Evaluation ,Balloon dilatation -- Evaluation ,Health - Abstract
Efficacy and major clinical end points were compared in 61 patients treated with a Stack autoperfusion balloon versus 36 patients who received a Palmaz-Schatz stent for acute or threatened closure during coronary angioplasty. The groups were comparable regarding baseline clinical characteristics. Procedural success was achieved in 43 patients (70%) treated with an autoperfusion balloon versus 34 patients (94%) who received a stent (p 50%) occurred in 13 patients with autoperfusion (30%) versus 3 patients with stents (12%) (p = NS). There was no difference in event-free survival during follow-up. Thus, both interventions were equally successful in the treatment of acute and threatened closure. More emergency surgery was performed in the autoperfusion balloon group, whereas a higher subacute reclosure rate was seen in the stent group. At 3-month follow-up, there were no significant differences regarding reclosure, restenosis, and event-free survival.
- Published
- 1994
319. Inadequate management of blood pressure in a hypertensive population
- Author
-
Sechi, Leonardo A., Zingaro, Laura, Bartoli, Ettore, Ward, Harry J., Pinto-Sietsma, Sara-Joan, Hillege, Hans L., Janssen, Wilbert M.T., Berlowitz, Dan R., Ash, Arlene S., and Moskowitz, Mark A.
- Subjects
Hypertension -- Care and treatment ,Aged men -- Care and treatment - Published
- 1999
320. Physical Activity in Pediatric Pulmonary Arterial Hypertension Measured by Accelerometry
- Author
-
Zijlstra, Willemijn M. H., Ploegstra, Mark-Jan, Vissia-Kazemier, Theresia, Roofthooft, Marcus T. R., Sarvaas, Gideon du Marchie, Bartelds, Beatrijs, Rackowitz, Annette, van den Heuvel, Freek, Hillege, Hans L., Plasqui, Guy, Berger, Rolf M. F., RS: NUTRIM - R3 - Respiratory & Age-related Health, RS: NUTRIM - HB/BW section B, and RS: NUTRIM - R1 - Metabolic Syndrome
- Subjects
pediatrics ,physical activity ,CHILDREN ,CATHETERIZATION ,EXERCISE CAPACITY ,6-MINUTE WALK TEST ,INSIGHTS ,QUALITY-OF-LIFE ,pulmonary arterial hypertension ,REGISTRY ,REPRODUCIBILITY ,accelerometry ,HEART ,CLINICAL-TRIALS - Abstract
Rationale: The development of evidence-based treatment guidelines for pediatric pulmonary arterial hypertension (PAH) is hampered by lack of pediatric clinical trials. Trial design is hampered by lack of a feasible clinical endpoint in this population. Objectives: To evaluate the use of accelerometry for measuring physical activity (PA) in pediatric PAH and to investigate its correlation with clinical disease severity markers. Methods: We included children from the Dutch National Network for Pediatric Pulmonary Hypertension. Control patients were recruited from the outpatient cardiology clinic of the Beatrix Children's Hospital. Children were asked to wear the accelerometer for 7 days. Vector magnitude counts per minute (VMCPM) and time per day spent in different PA intensity levels were defined as accelerometer outcomes. Measurements and Main Results: VM CPM was lower in children withPAH(n = 29) than in controls (n = 60; 647 vs. 921; P
- Published
- 2017
321. What Is Real-World Data (RWD)?: A Review of Definitions Based on Literature and Stakeholder Interviews
- Author
-
Makady, Amr, de Boer, Anthonius, Hillege, Hans, Klungel, Olaf, Goettsch, Wim, Pharmacoepidemiology and Clinical Pharmacology, and Afd Pharmacoepi & Clinical Pharmacology
- Subjects
Real-world evidence ,Health Policy ,Taverne ,Stakeholder definitions ,Public Health, Environmental and Occupational Health ,Definitions ,Review ,Real-world data ,Real-world studies - Abstract
Background: Despite increasing recognition of the value of real-world data (RWD), consensus on the definition of RWD is lacking. Objectives: To review definitions publicly available for RWD to shed light on similarities and differences between them. Methods: A literature review and stakeholder interviews were used to compile data from eight groups of stakeholders. Data from documents and interviews were subjected to coding analysis. Definitions identified were classified into four categories: 1) data collected in a non-randomized controlled trial setting, 2) data collected in a non-interventional/non-controlled setting, 3) data collected in a non-experimental setting, and 4) others (i.e., data that do not fit into the other three categories). The frequency of definitions identified per category was recorded. Results: Fifty-three documents and 20 interviews were assessed. Thirty-eight definitions were identified: 20 out of 38 definitions (53%) were category 1 definitions, 9 (24%) were category 2 definitions, 5 (13%) were category 3 definitions, and 4 (11%) were category 4 definitions. Differences were identified between, and within, definition categories. For example, opinions differed on the aspects of intervention with which non-interventional/non-controlled settings should abide. No definitions were provided in two interviews or identified in 33 documents. Conclusions: Most of the definitions defined RWD as data collected in a non-randomized controlled trial setting. A considerable number of definitions, however, diverged from this concept. Moreover, a significant number of authors and stakeholders did not have an official, institutional definition for RWD. Persisting variability in stakeholder definitions of RWD may lead to disparities among different stakeholders when discussing RWD use in decision making.
- Published
- 2017
322. Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial
- Author
-
Liu, Licette C.Y., Valente, Mattia A.E., Postmus, Douwe, O’Connor, Christopher M., Metra, Marco, Dittrich, Howard C., Ponikowski, Piotr, Teerlink, John R., Cotter, Gad, Davison, Beth, Cleland, John G.F., Givertz, Michael M., Bloomfield, Daniel M., van Veldhuisen, Dirk J., Hillege, Hans L., van der Meer, Peter, Voors, Adriaan A., Methods in Medicines evaluation & Outcomes research (M2O), Cardiovascular Centre (CVC), Life Course Epidemiology (LCE), Groningen Kidney Center (GKC), Value, Affordability and Sustainability (VALUE), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), Royal Brompton & Harefield NHS Foundation Trust, and National Institute for Health Research
- Subjects
Subpopulation treatment effect pattern plot ,OUTCOMES ,Science & Technology ,Cardiac & Cardiovascular Systems ,SUBSETS ,Acute heart failure ,R1 ,RANDOMIZED-TRIALS ,SUBGROUP ANALYSES ,Rolofylline ,Treatment heterogeneity ,CLINICAL-USE ,Cardiovascular System & Hematology ,RECEPTOR ANTAGONIST ROLOFYLLINE ,PERSONALIZED MEDICINE ,Cardiovascular System & Cardiology ,1115 Pharmacology And Pharmaceutical Sciences ,Pharmacology & Pharmacy ,PREDICTORS ,Life Sciences & Biomedicine ,Biomarkers - Abstract
Background: \ud \ud Over the last 50 years, clinical trials of novel interventions for acute heart failure (AHF) have, with few exceptions, been neutral or shown harm. We hypothesize that this might be related to a differential response to pharmacological therapy.\ud \ud Methods: \ud \ud We studied the magnitude of treatment effect of rolofylline across clinical characteristics and plasma biomarkers in 2033 AHF patients and derived a biomarker-based responder sum score model. Treatment response was survival from all-cause mortality through day 180.\ud \ud Results: \ud \ud In the overall study population, rolofylline had no effect on mortality (HR 1.03, 95% CI 0.82–1.28, p = 0.808). We found no treatment interaction across clinical characteristics, but we found interactions between several biomarkers and rolofylline. The biomarker-based sum score model included TNF-R1α, ST2, WAP four-disulfide core domain protein HE4 (WAP-4C), and total cholesterol, and the score ranged between 0 and 4. In patients with score 4 (those with increased TNF-R1α, ST2, WAP-4C, and low total cholesterol), treatment with rolofylline was beneficial (HR 0.61, 95% CI 0.40–0.92, p = 0.019). In patients with score 0, treatment with rolofylline was harmful (HR 5.52, 95% CI 1.68–18.13, p = 0.005; treatment by score interaction p
- Published
- 2017
323. Plasma biomarkers to predict or rule out early post-discharge events in patients discharged after an acute heart failure hospital admission
- Author
-
Demissei, Biniyam G., Postmus, Douwe, Cleland, John G.F., O’Connor, Christopher M., Metra, Marco, Ponikowski, Piotr, Teerlink, John R., Cotter, Gad, Davison, Beth A., Givertz, Michael M., Bloomfield, Daniel M., van Veldhuisen, Dirk J., Dittrich, Howard, Hillege, Hans L., and Voors, Adriaan A.
- Abstract
Aim:\ud Improved prediction of early post-discharge death or rehospitalization after admission for acute heart failure is a major unmet need. We evaluated the value of biomarkers to predict either low or high risk for early post-discharge events.\ud \ud Methods and results:\ud A total of 1653 patients enrolled in the PROTECT trial who were discharged alive and with available blood samples were included. Forty-seven biomarkers were serially evaluated in these patients. Measurement closest to discharge was used to evaluate the predictive value of biomarkers for low and high post-discharge risk. Patients were classified as ‘low risk’ if post-discharge 30-day risk of death or heart failure rehospitalization was 20% was used to define ‘high risk’. Cut-off values that yielded a 95% negative predictive value and a 20% positive predictive value were identified for each biomarker. Partial area under the receiver operating characteristic curve (pAUC) in the high-sensitivity and high-specificity regions was calculated to compare low-risk and high-risk predictive values. Of patients analysed, 193 (11.7%) patients reached the 30-day death or heart failure rehospitalization outcome. We found marked differences between low-risk and high-risk predictors. Cardiac-specific troponin I was the strongest biomarker for low-risk prediction (pAUC = 0.552, 95% confidence interval 0.52–0.58) while endothelin-1 showed better performance for high-risk prediction (pAUC = 0.560, 95% confidence interval 0.53–0.59). Several biomarkers (individually and in combination) provided added predictive value, on top of a clinical model, in both low-risk and high-risk regions.\ud \ud Conclusion:\ud Different biomarkers predicted low risk vs. high risk of early post-discharge death or heart failure readmission in patients hospitalized for acute heart failure.
- Published
- 2017
324. A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure
- Author
-
Sharma, Abhinav, Demissei, Biniyam G., Tromp, Jasper, Hillege, Hans L., Cleland, John G.F., O'Connor, Christopher M., Metra, Marco, Ponikowski, Piotr, Teerlink, John R., Davison, Beth A., Givertz, Michael M., Bloomfield, Daniel M., Dittrich, Howard, van Veldhuisen, Dirk J., Cotter, Gad, Ezekowitz, Justin A., Khan, Mohsin A.F., Voors, Adriaan A., Royal Brompton & Harefield NHS Foundation Trust, National Institute for Health Research, Life Course Epidemiology (LCE), Cardiovascular Centre (CVC), and Groningen Kidney Center (GKC)
- Subjects
Cardiac & Cardiovascular Systems ,Acute heart failure ,Biomarkers ,Diabetes ,Inflammation ,Network analysis ,Periostin ,Acute Disease ,Diabetes Mellitus ,Heart Failure ,Humans ,Cardiology and Cardiovascular Medicine ,1102 Cardiovascular Medicine And Haematology ,GLUCOSE ,CLINICAL CHARACTERISTICS ,ANTAGONIST ,REPAIR ,OUTCOMES ,Science & Technology ,MORTALITY ,ASSOCIATION ,R1 ,ROLOFYLLINE ,Cardiovascular System & Hematology ,PROTECT ,Cardiovascular System & Cardiology ,Life Sciences & Biomedicine - Abstract
Aims: \ud \ud It is unclear whether distinct pathophysiological processes are present among patients with acute heart failure (AHF), with and without diabetes. Network analysis of biomarkers may identify correlative associations that reflect different pathophysiological pathways.\ud Methods and results: \ud \ud We analysed a panel of 48 circulating biomarkers measured within 24 h of admission for AHF in a subset of patients enrolled in the PROTECT trial. In patients with and without diabetes, we performed a network analysis to identify correlations between measured biomarkers. Compared with patients without diabetes (n = 1111), those with diabetes (n = 922) had a higher prevalence of ischaemic heart disease and traditional coronary risk factors. After multivariable adjustment, patients with and without diabetes had significantly different levels of biomarkers across a spectrum of pathophysiological domains, including inflammation (TNFR-1a, periostin), cardiomyocyte stretch (BNP), angiogenesis (VEGFR, angiogenin), and renal function (NGAL, KIM-1) (adjusted P-value
- Published
- 2017
325. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies
- Author
-
Makady, Amr, Ham, Renske Ten, de Boer, Anthonius, Hillege, Hans, Klungel, Olaf, Goettsch, Wim, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Life Course Epidemiology (LCE), Cardiovascular Centre (CVC), and Groningen Kidney Center (GKC)
- Subjects
Comparative Effectiveness Research ,Consensus ,Technology Assessment, Biomedical ,IMPROVE ,media_common.quotation_subject ,Cost-Benefit Analysis ,Psychological intervention ,Guidelines as Topic ,Public administration ,Interviews as Topic ,03 medical and health sciences ,0302 clinical medicine ,Excellence ,Health care ,Agency (sociology) ,Prohibitins ,Taverne ,DECISIONS ,TOOL ,Medicine ,Humans ,Quality (business) ,030212 general & internal medicine ,PERSPECTIVE ,Policy Making ,real-world evidence ,relative effectiveness assessment ,Reimbursement ,media_common ,Evidence-Based Medicine ,real-world data ,business.industry ,030503 health policy & services ,Health Policy ,Public Health, Environmental and Occupational Health ,Stakeholder ,Health technology ,Health Care Costs ,policy study ,APPROVAL ,Europe ,TRIALS ,MEDICINES ,Insurance, Health, Reimbursement ,Government Regulation ,0305 other medical science ,business - Abstract
Background: Randomized controlled trials provide robust data on the efficacy of interventions rather than on effectiveness. Health technology assessment (HTA) agencies worldwide are thus exploring whether real-world data (RWD) may provide alternative sources of data on effectiveness of interventions. Presently, an overview of HTA agencies' policies for RWD use in relative effectiveness assessments (REA) is lacking. Objectives: To review policies of six European HTA agencies on RWD use in REA of drugs. A literature review and stakeholder interviews were conducted to collect information on RWD policies for six agencies: the Dental and Pharmaceutical Benefits Agency (Sweden), the National Institute for Health and Care Excellence (United Kingdom), the Institute for Quality and Efficiency in Healthcare (Germany), the High Authority for Health (France), the Italian Medicines Agency (Italy), and the National Healthcare Institute (The Netherlands). The following contexts for RWD use in REA of drugs were reviewed: initial reimbursement discussions, pharmacoeconomic analyses, and conditional reimbursement schemes. We identified 13 policy documents and 9 academic publications, and conducted 6 interviews. Results: Policies for RWD use in REA of drugs notably differed across contexts. Moreover, policies differed between HTA agencies. Such variations might discourage the use of RWD for HTA. Conclusions: To facilitate the use of RWD for HTA across Europe, more alignment of policies seems necessary. Recent articles and project proposals of the European network of HTA may provide a starting point to achieve this. Copyright (C) 2017, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.
- Published
- 2017
326. Conditional financing in health technology assessment practice: The Dutch experience
- Author
-
Nijmeijer, Hugo, van Veelen, Ard, De Boer, Anthonius, Hillege, Hans, Klungel, Olaf, Goettsch, Wim, Makady, Amr, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology
- Subjects
clinical article ,conference abstract ,financial management ,information processing ,reimbursement ,decision making ,outcomes research ,study design ,Taverne ,biomedical technology assessment ,human ,outcome assessment ,scientist ,Netherlands - Abstract
INTRODUCTION: In 2007, the National Healthcare Institute (ZIN) initiated conditional financing (CF) of expensive hospital drugs as an example of conditional reimbursement schemes (CRS). CF is a 4-year procedure encompassing initial HTA assessment (T = 0) followed by additional data collection via outcomes research (separately assessing appropriate use & cost-effectiveness in routine practice) and re-assessment (T = 4). This study aims to review performance and experiences with CF in the Netherlands to date. METHODS: All dossiers for drugs that underwent the full CF procedure were reviewed. Using a standardized data abstraction form, two researchers independently extracted information on procedural, methodological and decision-making aspects (that is, related to implemented outcomes research, evidence assessment and appraisal). A scoring algorithm was used to assess all three aspects. RESULTS: Fourty-seven candidates were nominated for CF; fourty-four underwent T = 0 assessments and eleven T = 4 assessments. The procedure extended beyond 4 years for 10/11 candidates. For the eleven candidates, applicants clearly defined study designs and data collection methods for outcomes research proposals addressing 16/22 research questions posed in T = 0 reports. ZIN provided discussion points and recommendations regarding research proposals for 18/22 research questions. Applicants implemented recommendations fully in 8/22 cases and partially in 12/22. Sufficient data was available at T = 4 to answer 15/22 research questions posed at T = 0. However, discussion points remained regarding implemented outcomes research for all eleven candidates at T = 4. ZIN advised to continue reimbursement for nine candidates and to stop reimbursement for two. For six of the nine candidates, reimbursement was continued on the basis of conditions relating to additional evidence generation beyond T = 4. CONCLUSIONS: Theoretically, CF provides a valuable option for enabling quick but conditional access to medicines in the Netherlands. However, procedural, methodological and decision-making considerations related to scheme design and implementation may affect its value in decision-making practice.
- Published
- 2017
327. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF
- Author
-
Ferreira, João Pedro, Rossignol, Patrick, Machu, Jean-Loup, Sharma, Abhinav, Girerd, Nicolas, Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos, Hillege, Hans L., Lang, Chim C., Ter Maaten, Jozine, Metra, Marco, Ng, Leong, Ponikowski, Piotr, Samani, Nilesh J., van Veldhuisen, Dirk J., Zwinderman, Aeilko H., Voors, Adriaan, Zannad, Faiez, Life Course Epidemiology (LCE), Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), APH - Methodology, Epidemiology and Data Science, Royal Brompton & Harefield NHS Foundation Trust, and National Institute for Health Research
- Subjects
Adherence ,Mineralocorticoid receptor antagonists ,Observational ,Prescription ,Real-life ,Europe ,Heart Failure ,Humans ,Mineralocorticoid Receptor Antagonists ,Practice Patterns, Physicians' ,Prospective Studies ,Retrospective Studies ,Treatment Outcome ,Ventricular Function, Left ,Cardiology and Cardiovascular Medicine ,EUROBSERVATIONAL RESEARCH-PROGRAM ,Left ,Practice Patterns ,1102 Cardiovascular Medicine And Haematology ,MILD PATIENTS HOSPITALIZATION ,Ventricular Function ,cardiovascular diseases ,ASSOCIATION HFA ,RANDOMIZED ALDACTONE EVALUATION ,Physicians' ,AMBULATORY PATIENTS ,WORSENING RENAL-FUNCTION ,R1 ,EUROPEAN-SOCIETY ,ESC-HF PILOT ,Cardiovascular System & Hematology ,SYSTOLIC DYSFUNCTION ,SPIRONOLACTONE THERAPY - Abstract
Aims\ud \ud Mineralocorticoid receptor antagonists (MRAs) are recommended (unless contraindicated) to all patients with heart failure with reduced ejection fraction (HFrEF). However, MRAs are still largely underused in routine clinical practice. This study aims to describe the determinants and pattern of use of MRAs in HFrEF.\ud Methods and results\ud \ud BIOSTAT-CHF is a European multicentre, prospective study which enrolled patients suboptimally treated with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs) and/or beta-blockers, with the aim of optimizing guideline-based use of these agents. From the original 2516 subjects, this retrospective post hoc analysis included the 1325 patients with an indication for MRA therapy (i.e. left ventricular ejection fraction ≤35%, estimated glomerular filtration rate ≥30 mL/min/1.73 m2, K+ ≤5.0 mmol/L). The mean age was 66.1 ± 12.2 years. At baseline an MRA was prescribed to 741 (56%) patients. Patients who were prescribed MRAs at baseline were younger, more often male, had higher body mass index, lower sodium, higher proportion of hypertension history and ACEi/ARB prescription (all P < 0.05). Of the 1049 patients who completed the baseline plus the 9 month visit, 585 (56%) had an MRA prescribed at baseline and 662 (63%) had an MRA prescribed at 9 months. Among the 585 patients with MRA at baseline, 91 (16%) had discontinued therapy and among the 461 (44%) patients without MRA at baseline 168 (36%) had initiated therapy subsequently. MRA discontinuation was more likely in subjects with higher left ventricular ejection fraction and NYHA class III/IV (P < 0.05 for both). MRA prescription both at baseline and 9 months was not associated with the outcome of death or heart failure hospitalization (adjusted hazard ratio 1.02, 95% confidence interval 0.66–1.58; P = 0.93).\ud Conclusions\ud \ud In this prospective observational study across Europe, MRAs were largely under-prescribed and frequently discontinued. Owing to these dynamic changes, outcome inferences are inconclusive.
- Published
- 2017
328. Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure
- Author
-
Demissei, Biniyam G., Postmus, Douwe, Cleland, John G., O'Connor, Christopher M., Metra, Marco, Ponikowski, Piotr, Teerlink, John R., Cotter, Gad, Davison, Beth A., Givertz, Michael M., Bloomfield, Daniel M., van Veldhuisen, Dirk J., Dittrich, Howard C., Hillege, Hans L., Voors, Adriaan A., Cardiovascular Centre (CVC), Life Course Epidemiology (LCE), Groningen Kidney Center (GKC), and Value, Affordability and Sustainability (VALUE)
- Subjects
RISK ,OUTCOMES ,30-DAY READMISSION ,Low risk ,High risk ,MORTALITY ,LENGTH-OF-STAY ,ASCEND-HF ,Predictive value ,Acute heart failure ,Biomarker ,CLINICAL-USE ,ROLOFYLLINE ,SENSITIVITY TROPONIN-T ,Risk stratification ,Cardiology and Cardiovascular Medicine ,TRIAL - Abstract
AimImproved prediction of early post-discharge death or rehospitalization after admission for acute heart failure is a major unmet need. We evaluated the value of biomarkers to predict either low or high risk for early post-discharge events. Methods and resultsA total of 1653 patients enrolled in the PROTECT trial who were discharged alive and with available blood samples were included. Forty-seven biomarkers were serially evaluated in these patients. Measurement closest to discharge was used to evaluate the predictive value of biomarkers for low and high post-discharge risk. Patients were classified as low risk' if post-discharge 30-day risk of death or heart failure rehospitalization was 20% was used to define high risk'. Cut-off values that yielded a 95% negative predictive value and a 20% positive predictive value were identified for each biomarker. Partial area under the receiver operating characteristic curve (pAUC) in the high-sensitivity and high-specificity regions was calculated to compare low-risk and high-risk predictive values. Of patients analysed, 193 (11.7%) patients reached the 30-day death or heart failure rehospitalization outcome. We found marked differences between low-risk and high-risk predictors. Cardiac-specific troponin I was the strongest biomarker for low-risk prediction (pAUC = 0.552, 95% confidence interval 0.52-0.58) while endothelin-1 showed better performance for high-risk prediction (pAUC = 0.560, 95% confidence interval 0.53-0.59). Several biomarkers (individually and in combination) provided added predictive value, on top of a clinical model, in both low-risk and high-risk regions. ConclusionDifferent biomarkers predicted low risk vs. high risk of early post-discharge death or heart failure readmission in patients hospitalized for acute heart failure.
- Published
- 2017
329. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy
- Author
-
van den Broek, Stan A.J., van Veldhuisen, Dirk J., de Graeff, Pieter A., Landsman, Martin L.J., Hillege, Hans, and Lie, Kong I.
- Subjects
Congestive heart failure -- Prognosis ,Cardiomyopathy, Dilated -- Complications ,Oxygen consumption -- Measurement ,Health - Published
- 1992
330. Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure
- Author
-
Valente, Mattia A. E., Voors, Adriaan A., Damman, Kevin, Veldhuisen, Dirk J. Van, Massie, Barrie M., O'Connor, Christopher M., Metra, Marco, Ponikowski, Piotr, Teerlink, John R., Cotter, Gad, Davison, Beth, Cleland, John G. F., Givertz, Michael M., Bloomfield, Daniel M., Fiuzat, Mona, Dittrich, Howard C., Hillege, Hans L., Life Course Epidemiology (LCE), Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), and Methods in Medicines evaluation & Outcomes research (M2O)
- Subjects
Male ,Acute decompensated heart failure ,IMPACT ,heart failure ,Comorbidity ,Kidney ,Rolofylline ,Blood Urea Nitrogen ,Kidney Failure ,chemistry.chemical_compound ,Models ,80 and over ,IN-HOSPITAL MORTALITY ,Chronic ,Blood urea nitrogen ,Randomized Controlled Trials as Topic ,Aged, 80 and over ,Ejection fraction ,Middle Aged ,Survival Rate ,Treatment Outcome ,Creatinine ,Cardiology ,Biological Markers ,Female ,TRIAL ,Cardiology and Cardiovascular Medicine ,hospitalization ,medicine.medical_specialty ,Renal function ,Cardiorenal syndrome ,PRESSURE ,Models, Biological ,Predictive Value of Tests ,Internal medicine ,medicine ,Humans ,cardiorenal syndrome ,mortality ,Aged ,Follow-Up Studies ,Heart Failure ,Kidney Failure, Chronic ,Multivariate Analysis ,Purinergic P1 Receptor Antagonists ,Xanthines ,Intensive care medicine ,ANTAGONIST ,MEDICARE BENEFICIARIES ,business.industry ,Biological ,medicine.disease ,DYSFUNCTION ,MODEL ,ROLOFYLLINE ,chemistry ,PROTECT ,Heart failure ,business ,Biomarkers - Abstract
Background— Prior studies have demonstrated adverse risk associated with baseline and worsening renal function in acute heart failure, but none has modeled the trajectories of change in renal function and their impact on outcomes. Methods and Results— We used linear mixed models of serial measurements of blood urea nitrogen and creatinine to describe trajectories of renal function in 1962 patients with acute heart failure and renal dysfunction enrolled in the Placebo-Controlled Randomized Study of the Selective A 1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function study. We assessed risk of 180-day mortality and 60-day cardiovascular or renal readmission and used Cox regression to determine association between renal trajectories and outcomes. Compared with patients alive at 180 days, patients who died were older, had lower blood pressure and ejection fraction, and higher creatinine levels at baseline. On average for the entire cohort, creatinine rose from days 1 to 3 and increased further after discharge, with the trajectory dependent on the day of discharge. Blood urea nitrogen, creatinine, and the rate of change in creatinine from baseline were the strongest independent predictors of 180-day mortality and 60-day readmission, whereas the rate of change of blood urea nitrogen from baseline was not predictive of outcomes. Baseline blood urea nitrogen >35 mg/dL and increase in creatinine >0.1 mg/dL per day increased the risk of mortality, whereas stable or decreasing creatinine was associated with reduced risk. Conclusions— Patients with acute heart failure and renal dysfunction demonstrate variable rise and fall in renal indices during and immediately after hospitalization. Risk of morbidity and mortality can be predicted based on baseline renal function and creatinine trajectory during the first 7 days. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifiers: NCT00328692 and NCT00354458.
- Published
- 2014
331. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure
- Author
-
Voors, Adriaan A., Ouwerkerk, Wouter, Zannad, Faiez, van Veldhuisen, Dirk J., Samani, Nilesh J., Ponikowski, Piotr, Ng, Leong L., Metra, Marco, ter Maaten, Jozine M., Lang, Chim C., Hillege, Hans L., van der Harst, Pim, Filippatos, Gerasimos, Dickstein, Kenneth, Cleland, John G.F., Anker, Stefan D., Zwinderman, Aeilko H., Graduate School, Epidemiology and Data Science, Dermatology, APH - Methodology, ACS - Amsterdam Cardiovascular Sciences, Cardiovascular Centre (CVC), Life Course Epidemiology (LCE), and Groningen Kidney Center (GKC)
- Subjects
Male ,ACUTE MYOCARDIAL-INFARCTION ,CLINICAL-OUTCOMES ,Left ,DIAGNOSIS ,Heart failure hospitalization ,Risk Assessment ,Ventricular Function, Left ,READMISSION ,Prediction model ,Predictive Value of Tests ,Risk Factors ,Ventricular Function ,Humans ,Heart failure ,Mortality ,Aged ,Europe ,Female ,Heart Failure ,Hospital Mortality ,Hospitalization ,Prognosis ,Prospective Studies ,Survival Rate ,Program Development ,Cardiology and Cardiovascular Medicine ,ASSOCIATION HFA ,RISK PREDICTION ,R1 ,EUROPEAN-SOCIETY ,SURVIVAL ,HIGH-DENSITY-LIPOPROTEIN ,TASK-FORCE - Abstract
Introduction: \ud \ud From a prospective multicentre multicountry clinical trial, we developed and validated risk models to predict prospective all-cause mortality and hospitalizations because of heart failure (HF) in patients with HF.\ud Methods and results: \ud \ud BIOSTAT-CHF is a research programme designed to develop and externally validate risk models to predict all-cause mortality and HF hospitalizations. The index cohort consisted of 2516 patients with HF from 69 centres in 11 European countries. The external validation cohort consisted of 1738 comparable patients from six centres in Scotland, UK. Patients from the index cohort had a mean age of 69 years, 27% were female, 83% were in New York Heart Association (NYHA) class II–III and the mean left ventricular ejection fraction (LVEF) was 31%. The full prediction models for mortality, hospitalization owing to HF, and the combined outcome, yielded c-statistic values of 0.73, 0.69, and 0.71, respectively. Predictors of mortality and hospitalization owing to HF were remarkably different. The five strongest predictors of mortality were more advanced age, higher blood urea nitrogen and N-terminal pro-B-type natriuretic peptide, lower haemoglobin, and failure to prescribe a beta-blocker. The five strongest predictors of hospitalization owing to HF were more advanced age, previous hospitalization owing to HF, presence of oedema, lower systolic blood pressure and lower estimated glomerular filtration rate. Patients from the validation cohort were aged 74 years, 34% were female, 85% were in NYHA class II–III, and mean LVEF was 41%; c-statistic values for the full and compact model were comparable to the index cohort.\ud Conclusion: \ud \ud A small number of variables, which are usually readily available in the routine clinical setting, provide useful prognostic information for patients with HF. Predictors of mortality were remarkably different from predictors of hospitalization owing to HF.
- Published
- 2016
332. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter
- Author
-
Crijns, Harry J., Van Gelder, Isabelle C., Van Gilst, Wiek H., Hillege, Hans, Gosselink, A. Marcel, and Lie, Kong I.
- Subjects
Electric countershock -- Health aspects ,Atrial fibrillation -- Drug therapy ,Atrial flutter -- Drug therapy ,Health - Abstract
The sequential use of different types of antiarrhythmic drugs may improve arrhythmia prognosis in chronic atrial fibrillation or flutter after successful electrical cardioversion. The rationale for serial treatment is that the arrhythmogenic mechanism may vary between patients, leading to different responses to 1 specific drug. To investigate this issue prospectively, 127 patients having chronic fibrillation or flutter exclusively, underwent serial drug treatment with flecinide (stage I) followed by sotalol or, if contraindicated, quinidine (stage II) and eventually amiodarone (stage III). Stages II and III were entered after electrical recardioversion for a recurrence during stages I or II, respectively. Calculated on an actuarial basis, the 2-year cumulative percentage of patients free of the arrhythmia increased from 31% after stage 1 to 63% at the end of serial treatment. To reach this result, a mean of 1.8 [+ or -] 0.8 cardioversions per patient were needed, with S3 patients progressing to stage II and 34 to stage III. Sixteen patients stopped serial treatment prematurely and 15 patients were considered to have intractable atrial fibrillation at the end of stage ill. incidence of prearrhythmia was low. Multivariate analysis disclosed that an older age, in combination with a large number of previous episodes of arrhythmia, a long previous duration of arrhythmia and presence of mitral valve disease, were predictive for medical refractoriness during serial treatment. it is concluded that serial treatment may improve arrhythmia prognosis in atrial fibriliation or flutter, with an acceptable incidence of proarrhythmic events. (Am J Cardiol 1991;68:33S-341), Electrical cardioversion, defibrillation, is a countershock delivered to restore the heart's normal rhythm. Chronic atrial fibrillation or flutter (excessively fast heartbeat involving the atrium, the upper heart chamber), is often a side effect of this procedure, and may occur despite treatment with antiarrhythmic drugs. Usually only class IA antiarrhythmic drugs are used, but sequentially changing the type of drug after recurrence of arrhythmias might improve the outcome. The effectiveness of serial use of flecainide, sotalol or quinidine, and amiodarone in treating 186 patients with chronic atrial fibrillation following cardioversion was evaluated. Flecainide was given to 127 patients during stage I of the study. After two years, 31 percent of these patients still had a normal heart rhythm. During this stage, two patients died, and eight patients discontinued treatment due to side effects, including worsening of arrhythmia. Fifty-three patients entered stage II, treatment with quinidine or sotalol, while 12 patients entered stage III treatment with amiodarone immediately after stage I. After 24 months, 42 percent of 53 patients in stage II had normal rhythm, while 5 patients had adverse effects. Thirty-four patients entered stage III treatment, and after 24 months, 40 percent had normal heart rhythm, while two patients developed a skin allergy and one died of a heart attack. Patients who did not respond to this serial drug therapy tended to be older, to have a higher number of previous arrhythmic episodes, long duration of arrhythmia, and to have mitral valve disease. The study indicates that this type of serial treatment can reduce the rate of recurrence of atrial fibrillation from 50 to approximately 35 percent. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1991
333. A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction
- Author
-
Brugemann, Johan, van der Meer, Jan, Takens, Bert H., Hillege, Hans, and Lie, Kong I.
- Subjects
Anistreplase -- Evaluation ,Heart attack -- Drug therapy ,Thrombolytic drugs -- Evaluation ,Streptokinase -- Evaluation ,Health - Abstract
Acute myocardial infarction (AMI), or heart attack, is a condition in which one or more of the arteries supplying blood to the heart becomes blocked by a blood clot, depriving the cardiac muscle of oxygen (myocardial ischemia). If not treated immediately, serious heart damage and death can result. One accepted treatment for AMI is the administration of thrombolytic (clot-dissolving) agents such as streptokinase or tissue-type plasminogen activator, and anistreplase, which restore blood flow through the blocked artery by dissolving the occlusive clot. Thrombolytic therapy is effective in the majority of AMI patients, but in as many as 30 to 40 percent, reperfusion (restoration of blood flow) is not achieved, irrespective of the drug given. In some cases, the configuration of the coronary occlusion may be the cause of this failure, but inhibition of the thrombolytic activity of the drug has not been ruled out. It has been suggested that a necessary condition for thrombolytic therapy to be effective may be a lytic state (low blood concentration of fibrinogen, a factor involved in blood clotting), and that when this is not present, a thrombolysis-resistant state may prevail. To evaluate the possibility that drug resistance may explain some cases of thrombolytic failure, a study was done with 58 consecutive AMI patients. Thrombolytic therapy was instituted within four hours of symptom onset. Patients were divided into those manifesting lytic states (52 patients) and those in non-lytic states (six patients) on the basis of blood fibrinogen concentrations 90 minutes after initiation of drug treatment. The overall patency rate (percentage of occluded arteries that were restored to acceptable levels of blood flow) was 74 percent; but the rate was significantly different for the lytic and non-lytic groups (83 percent versus 0 percent, respectively). The presence of an as-yet unidentified factor which specifically inhibits thrombolytic activity may be the reason for the failure to achieve reperfusion. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1990
334. Sex differences in patients with repaired tetralogy of Fallot support a tailored approach for males and females: a cardiac magnetic resonance study.
- Author
-
Hagdorn, Quint A. J., Beurskens, Niek E. G., Gorter, Thomas M., Eshuis, Graziëlla, Hillege, Hans L., Lui, George K., Ceresnak, Scott R., Chan, Frandics P., van Melle, Joost P., Berger, Rolf M. F., and Willems, Tineke P.
- Abstract
Purpose Substantial differences between sexes exist with respect to cardiovascular diseases, including congenital heart disease. Nevertheless, clinical decisions in the long-term follow-up of patients with repaired tetralogy of Fallot (rTOF) are currently based on unisex thresholds for cardiac magnetic resonance (CMR) measurements. This study aimed to assess whether sex differences exist in cardiac adaptation to hemodynamic loading conditions in patients with rTOF. Methods and Results This cross-sectional, two-center, combined pediatric and adult cohort included 320 rTOF patients (163 males, 51%) who underwent routine CMR. Despite similar age (median and interquartile range [m + IQR] 23.4 [15.2–34.4] years), surgical history, and hemodynamic loading, males with rTOF demonstrated higher biventricular CMR-derived volumes and masses, indexed for body surface area, compared to females (e.g. m + IQR right ventricular (RV) end-diastolic volume: males 123 [100–151] mL/m
2 , females 114 [94–131] mL/m2 , P = 0.007). Sex-specific Z-scores of biventricular volumes and masses were similar for males and females. RV volumes and masses correlated with hemodynamic loading, but these relations did not differ between sexes. Biventricular ejection fraction (EF) appeared to be lower in male patients, compared to female patients (e.g. m + IQR RVEF: males 48 [43–54]%, females 52 [46–57]%, P < 0.001). Conclusion Indexed ventricular volumes and masses are higher in males with rTOF, compared to females, similar to the healthy population. RV hypertrophy and dilatation correlated to loading conditions similarly for both sexes. However, under comparable loading conditions, males demonstrated more severe functional impairment. These results indicate that sex-differences should no longer be ignored in treatment strategies, including timing of pulmonary valve replacement. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
335. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.
- Author
-
ter Maaten, Jozine M., Martens, Pieter, Damman, Kevin, Dickstein, Kenneth, Ponikowski, Piotr, Lang, Chim C., Ng, Leong L., Anker, Stefan D., Samani, Nilesh J., Filippatos, Gerasimos, Cleland, John G., Zannad, Faiez, Hillege, Hans L., van Veldhuisen, Dirk J., Metra, Marco, Voors, Adriaan A., and Mullens, Wilfried
- Abstract
Background: Loop diuretics are frequently prescribed to patients with heart failure and reduced ejection fraction (HFrEF) for the treatment of congestion; however, they might hamper uptitration of inhibitors of the renin–angiotensin system. Methods: Loop diuretic dose at baseline was recorded in 2338 patients with HFrEF enrolled in BIOSTAT-CHF, an international study of HF patients on loop diuretic therapy who were eligible for uptitration of angiotensin-converting enzyme inhibitors (ACEi)/mineralocorticoid receptor antagonists (MRA). The association between loop diuretic dose and uptitration of ACEi/MRA to percentage of target dose was adjusted for a previously published model for likelihood of uptitration and a propensity score. Results: Baseline median loop diuretic dose was 40 [40–100] mg of furosemide or equivalent. Higher doses of loop diuretics were associated with higher NYHA class and higher levels of NT-proBNP, more severe signs and symptoms of congestion, more frequent MRA use, and lower doses of ACEi reached at 3 and 9 months (all P < 0.01). After propensity adjustment, higher doses of loop diuretics remained significantly associated with poorer uptitration of ACEi (Beta per log doubling of loop diuretic dose: − 1.66, P = 0.021), but not with uptitration of MRAs (P = 0.758). Higher doses of loop diuretics were independently associated with an increased risk of all-cause mortality or HF hospitalization [HR per doubling of loop diuretic dose: 1.06 (1.01–1.12), P = 0.021]. Conclusions: Higher doses of loop diuretics limited uptitration of ACEi in patients with HFrEF and were associated with a higher risk of death and/or HF hospitalization, independent of their lower likelihood of uptitration and higher baseline risk. This figure was created with images adapted from Servier Medical Art licensed under a Creative Commons Attribution 3.0 [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
336. Selenium and outcome in heart failure.
- Author
-
Bomer, Nils, Grote Beverborg, Niels, Hoes, Martijn F., Streng, Koen W., Vermeer, Mathilde, Dokter, Martin M., IJmker, Jan, Anker, Stefan D., Cleland, John G.F., Hillege, Hans L., Lang, Chim C., Ng, Leong L., Samani, Nilesh J., Tromp, Jasper, Veldhuisen, Dirk J., Touw, Daan J., Voors, Adriaan A., Meer, Peter, van Veldhuisen, Dirk J, and van der Meer, Peter
- Subjects
INDUCTIVELY coupled plasma mass spectrometry ,REACTIVE oxygen species ,SELENIUM ,HEART failure ,INTERMITTENT claudication ,LEFT heart ventricle ,RESEARCH ,RESEARCH methodology ,MEDICAL care ,ACE inhibitors ,MEDICAL cooperation ,EVALUATION research ,CARDIOVASCULAR system ,COMPARATIVE studies ,QUALITY of life ,QUESTIONNAIRES ,RESEARCH funding ,HEART physiology ,ANGIOTENSIN receptors ,STROKE volume (Cardiac output) ,LONGITUDINAL method - Abstract
Aims: Severe deficiency of the essential trace element selenium can cause myocardial dysfunction although the mechanism at cellular level is uncertain. Whether, in clinical practice, moderate selenium deficiency is associated with worse symptoms and outcome in patients with heart failure is unknown.Methods and Results: BIOSTAT-CHF is a multinational, prospective, observational cohort study that enrolled patients with worsening heart failure. Serum concentrations of selenium were measured by inductively coupled plasma mass spectrometry. Primary endpoint was a composite of all-cause mortality and hospitalization for heart failure; secondary endpoint was all-cause mortality. To investigate potential mechanisms by which selenium deficiency might affect prognosis, human cardiomyocytes were cultured in absence of selenium, and mitochondrial function and oxidative stress were assessed. Serum selenium concentration (deficiency) was <70 μg/L in 485 (20.4%) patients, who were older, more often women, had worse New York Heart Association class, more severe signs and symptoms of heart failure and poorer exercise capacity (6-min walking test) and quality of life (Kansas City Cardiomyopathy Questionnaire). Selenium deficiency was associated with higher rates of the primary endpoint [hazard ratio (HR) 1.23; 95% confidence interval (CI) 1.06-1.42] and all-cause mortality (HR 1.52; 95% CI 1.26-1.86). In cultured human cardiomyocytes, selenium deprivation impaired mitochondrial function and oxidative phosphorylation, and increased intracellular reactive oxygen species levels.Conclusions: Selenium deficiency in heart failure patients is independently associated with impaired exercise tolerance and a 50% higher mortality rate, and impaired mitochondrial function in vitro, in human cardiomyocytes. Clinical trials are needed to investigate the effect of selenium supplements in patients with heart failure, especially if they have low plasma concentrations of selenium. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
337. Serial Measurements of N-Terminal Pro-B-Type Natriuretic Peptide Serum Level for Monitoring Pulmonary Arterial Hypertension in Children.
- Author
-
Said, Fatema, Haarman, Meindina G., Roofthooft, Marcus T.R., Hillege, Hans L., Ploegstra, Mark-Jan, and Berger, Rolf M.F.
- Abstract
Objective: To assess the association between serially measured N-terminal pro-B-type natriuretic peptide (NT-proBNP) serum levels and disease severity in children with pulmonary arterial hypertension (PAH), and to assess its predictive value for death or (heart-)lung transplantation.Study Design: This was a longitudinal cohort study of the Dutch National Network for Pediatric Pulmonary Hypertension conducted between 2003 and 2017. Data on NT-proBNP and disease severity markers (World Health Organization Functional Class [WHO-FC], 6-minute walking distance [6MWD], and tricuspid annular plane systolic excursion [TAPSE]) were collected every 3 to 6 months from 82 children with PAH. The outcome measure was death or (heart-)lung transplantation. Also, NT-proBNP levels over time were compared between survivors and nonsurvivors.Results: The median patient age was 8.8 years (IQR, 4.6-13.5 years), and 61% were female. The median duration of follow-up was 4.8 years (IQR, 1.9-10.0 years). At all times during the course of disease, higher NT-proBNP levels were associated with higher WHO-FC (β = 0.526; 95% CI, 0.451-0.600), lower 6MWD z-score (β = -0.587; 95% CI, -0.828 to -0.346), lower TAPSE z-score (β = -0.783; 95% CI, -1.016 to -0.549), and elevated risk of death or (heart-)lung transplantation (hazard ratio 16.61; 95% CI, 7.81-35.33). Compared with survivors, nonsurvivors had NT-proBNP levels that were higher at first measurement and increased exponentially over time (P = .005). Changes in NT-proBNP serum level over time were predictive of outcome.Conclusions: Throughout the disease course of pediatric PAH, serial measurements of NT-proBNP are associated with disease severity and transplant-free survival. Monitoring NT-proBNP levels over time provides important prognostic information that can support clinical decision making in combination with other established prognostic markers. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
338. A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure.
- Author
-
Sama, Iziah E., Woolley, Rebecca J., Nauta, Jan F., Romaine, Simon P.R., Tromp, Jasper, Maaten, Jozine M., Meer, Peter, Lam, Carolyn S.P., Samani, Nilesh J., Ng, Leong L., Metra, Marco, Dickstein, Kenneth, Anker, Stefan D., Zannad, Faiez, Lang, Chim C., Cleland, John G.F., Veldhuisen, Dirk J., Hillege, Hans L., Voors, Adriaan A., and Ter Maaten, Jozine M
- Subjects
HEART failure ,EPIDERMAL growth factor receptors ,SOMATOMEDIN ,CARDIOMYOPATHIES ,BLOOD proteins ,LEFT heart ventricle ,RESEARCH ,RESEARCH methodology ,ACE inhibitors ,MEDICAL care ,MEDICAL cooperation ,EVALUATION research ,CARDIOVASCULAR system ,COMPARATIVE studies ,STROKE volume (Cardiac output) ,ANGIOTENSIN receptors ,HEART physiology - Abstract
Aims: Heart failure (HF) is frequently caused by an ischaemic event (e.g. myocardial infarction) but might also be caused by a primary disease of the myocardium (cardiomyopathy). In order to identify targeted therapies specific for either ischaemic or non-ischaemic HF, it is important to better understand differences in underlying molecular mechanisms.Methods and Results: We performed a biological physical protein-protein interaction network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic HF. First, differentially expressed plasma protein biomarkers were identified in 1160 patients enrolled in the BIOSTAT-CHF study, 715 of whom had ischaemic HF and 445 had non-ischaemic HF. Second, we constructed an enriched physical protein-protein interaction network, followed by a pathway over-representation analysis. Finally, we identified key network proteins. Data were validated in an independent HF cohort comprised of 765 ischaemic and 100 non-ischaemic HF patients. We found 21/92 proteins to be up-regulated and 2/92 down-regulated in ischaemic relative to non-ischaemic HF patients. An enriched network of 18 proteins that were specific for ischaemic heart disease yielded six pathways, which are related to inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. We identified five key network proteins: acid phosphatase 5, epidermal growth factor receptor, insulin-like growth factor binding protein-1, plasminogen activator urokinase receptor, and secreted phosphoprotein 1. Similar results were observed in the independent validation cohort.Conclusions: Pathophysiological pathways distinguishing patients with ischaemic HF from those with non-ischaemic HF were related to inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. The five key pathway proteins identified are potential treatment targets specifically for patients with ischaemic HF. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
339. Patient Preferences in the Medical Product Lifecycle.
- Author
-
Whitty, Jennifer A., de Bekker-Grob, Esther W., Cook, Nigel S., Terris-Prestholt, Fern, Drummond, Michael, Falchetto, Rocco, and Hillege, Hans L.
- Published
- 2020
- Full Text
- View/download PDF
340. Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets.
- Author
-
Cao, Thong H., Jones, Donald J.L., Voors, Adriaan A., Quinn, Paulene A., Sandhu, Jatinderpal K., Chan, Daniel C.S., Parry, Helen M., Mohan, Mohapradeep, Mordi, Ify R., Sama, Iziah E., Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos, Hillege, Hans L., Metra, Marco, Ponikowski, Piotr, Samani, Nilesh J., Van Veldhuisen, Dirk J., and Zannad, Faiez
- Subjects
HEART failure patients ,DISEASE progression ,TANDEM mass spectrometry ,PROLINE metabolism ,PROTEIN-protein interactions ,HEART failure treatment ,LEFT heart ventricle ,BLOOD plasma ,ACE inhibitors ,MEDICAL care ,PROTEOMICS ,CARDIOVASCULAR system ,MASS spectrometry ,STROKE volume (Cardiac output) ,ANGIOTENSIN receptors ,HEART physiology - Abstract
Aims: To provide insights into pathogenesis of disease progression and potential novel treatment targets for patients with heart failure by investigation of the plasma proteome using network analysis.Methods and Results: The plasma proteome of 50 patients with heart failure who died or were rehospitalised were compared with 50 patients with heart failure, matched for age and sex, who did not have an event. Peptides were analysed on two-dimensional liquid chromatography coupled to tandem mass spectrometry (2D LC ESI-MS/MS) in high definition mode (HDMSE). We identified and quantified 3001 proteins, of which 51 were significantly up-regulated and 46 down-regulated with more than two-fold expression changes in those who experienced death or rehospitalisation. Gene ontology enrichment analysis and protein-protein interaction networks of significant differentially expressed proteins discovered the central role of metabolic processes in clinical outcomes of patients with heart failure. The findings revealed that a cluster of proteins related to glutathione metabolism, arginine and proline metabolism, and pyruvate metabolism in the pathogenesis of poor outcome in patients with heart failure who died or were rehospitalised.Conclusions: Our findings show that in patients with heart failure who died or were rehospitalised, the glutathione, arginine and proline, and pyruvate pathways were activated. These pathways might be potential targets for therapies to improve poor outcomes in patients with heart failure. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
341. Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration
- Author
-
Cao, Qi, primary, Buskens, Erik, additional, Hillege, Hans L., additional, Jaarsma, Tiny, additional, Postma, Maarten, additional, and Postmus, Douwe, additional
- Published
- 2018
- Full Text
- View/download PDF
342. Association with outcomes and response to treatment of trimethylamine N‐oxide in heart failure: results from BIOSTAT‐CHF
- Author
-
Suzuki, Toru, primary, Yazaki, Yoshiyuki, additional, Voors, Adriaan A., additional, Jones, Donald J.L., additional, Chan, Daniel C.S., additional, Anker, Stefan D., additional, Cleland, John G., additional, Dickstein, Kenneth, additional, Filippatos, Gerasimos, additional, Hillege, Hans L., additional, Lang, Chim C., additional, Ponikowski, Piotr, additional, Samani, Nilesh J., additional, van Veldhuisen, Dirk J., additional, Zannad, Faiez, additional, Zwinderman, Aeilko H., additional, Metra, Marco, additional, and Ng, Leong L., additional
- Published
- 2018
- Full Text
- View/download PDF
343. Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction
- Author
-
Tromp, Jasper, primary, Westenbrink, B. Daan, additional, Ouwerkerk, Wouter, additional, van Veldhuisen, Dirk J., additional, Samani, Nilesh J., additional, Ponikowski, Piotr, additional, Metra, Marco, additional, Anker, Stefan D., additional, Cleland, John G., additional, Dickstein, Kenneth, additional, Filippatos, Gerasimos, additional, van der Harst, Pim, additional, Lang, Chim C., additional, Ng, Leong L., additional, Zannad, Faiez, additional, Zwinderman, Aelko H., additional, Hillege, Hans L., additional, van der Meer, Peter, additional, and Voors, Adriaan A., additional
- Published
- 2018
- Full Text
- View/download PDF
344. Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction
- Author
-
Santema, Bernadet T, primary, Kloosterman, Mariëlle, additional, Van Gelder, Isabelle C, additional, Mordi, Ify, additional, Lang, Chim C, additional, Lam, Carolyn S P, additional, Anker, Stefan D, additional, Cleland, John G, additional, Dickstein, Kenneth, additional, Filippatos, Gerasimos, additional, Van der Harst, Pim, additional, Hillege, Hans L, additional, Ter Maaten, Jozine M, additional, Metra, Marco, additional, Ng, Leong L, additional, Ponikowski, Piotr, additional, Samani, Nilesh J, additional, Van Veldhuisen, Dirk J, additional, Zwinderman, Aeilko H, additional, Zannad, Faiez, additional, Damman, Kevin, additional, Van der Meer, Peter, additional, Rienstra, Michiel, additional, and Voors, Adriaan A, additional
- Published
- 2018
- Full Text
- View/download PDF
345. The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
- Author
-
Savji, Nazir, primary, Meijers, Wouter C., additional, Bartz, Traci M., additional, Bhambhani, Vijeta, additional, Cushman, Mary, additional, Nayor, Matthew, additional, Kizer, Jorge R., additional, Sarma, Amy, additional, Blaha, Michael J., additional, Gansevoort, Ron T., additional, Gardin, Julius M., additional, Hillege, Hans L., additional, Ji, Fei, additional, Kop, Willem J., additional, Lau, Emily S., additional, Lee, Douglas S., additional, Sadreyev, Ruslan, additional, van Gilst, Wiek H., additional, Wang, Thomas J., additional, Zanni, Markella V., additional, Vasan, Ramachandran S., additional, Allen, Norrina B., additional, Psaty, Bruce M., additional, van der Harst, Pim, additional, Levy, Daniel, additional, Larson, Martin, additional, Shah, Sanjiv J., additional, de Boer, Rudolf A., additional, Gottdiener, John S., additional, and Ho, Jennifer E., additional
- Published
- 2018
- Full Text
- View/download PDF
346. The dynamics of self-care in the course of heart failure management: data from the IN TOUCH study
- Author
-
Lycholip, Edita, primary, Thon Aamodt, Ina, additional, Lie, Irene, additional, Šimbelytė, Toma, additional, Puronaitė, Roma, additional, Hillege, Hans, additional, de Vries, Arjen, additional, Kraai, Imke, additional, Stromberg, Anna, additional, Jaarsma, Tiny, additional, and Čelutkienė, Jelena, additional
- Published
- 2018
- Full Text
- View/download PDF
347. Normal Values of Corrected Heart-Rate Variability in 10-Second Electrocardiograms for All Ages
- Author
-
van den Berg, Marten E., primary, Rijnbeek, Peter R., additional, Niemeijer, Maartje N., additional, Hofman, Albert, additional, van Herpen, Gerard, additional, Bots, Michiel L., additional, Hillege, Hans, additional, Swenne, Cees A., additional, Eijgelsheim, Mark, additional, Stricker, Bruno H., additional, and Kors, Jan A., additional
- Published
- 2018
- Full Text
- View/download PDF
348. Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study
- Author
-
Brankovic, Milos, primary, Akkerhuis, K. Martijn, additional, van Boven, Nick, additional, Anroedh, Sharda, additional, Constantinescu, Alina, additional, Caliskan, Kadir, additional, Manintveld, Olivier, additional, Cornel, Jan Hein, additional, Baart, Sara, additional, Rizopoulos, Dimitris, additional, Hillege, Hans, additional, Boersma, Eric, additional, Umans, Victor, additional, and Kardys, Isabella, additional
- Published
- 2018
- Full Text
- View/download PDF
349. Reply
- Author
-
van Vark, Laura C., primary, Kardys, Isabella, additional, Boersma, Eric, additional, Hillege, Hans L., additional, and Akkerhuis, K. Martijn, additional
- Published
- 2018
- Full Text
- View/download PDF
350. Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction
- Author
-
de Boer, Rudolf A., primary, Nayor, Matthew, additional, deFilippi, Christopher R., additional, Enserro, Danielle, additional, Bhambhani, Vijeta, additional, Kizer, Jorge R., additional, Blaha, Michael J., additional, Brouwers, Frank P., additional, Cushman, Mary, additional, Lima, Joao A. C., additional, Bahrami, Hossein, additional, van der Harst, Pim, additional, Wang, Thomas J., additional, Gansevoort, Ron T., additional, Fox, Caroline S., additional, Gaggin, Hanna K, additional, Kop, Willem J., additional, Liu, Kiang, additional, Vasan, Ramachandran S., additional, Psaty, Bruce M., additional, Lee, Douglas S., additional, Hillege, Hans L., additional, Bartz, Traci M., additional, Benjamin, Emelia J., additional, Chan, Cheeling, additional, Allison, Matthew, additional, Gardin, Julius M., additional, Januzzi, James L., additional, Shah, Sanjiv J., additional, Levy, Daniel, additional, Herrington, David M., additional, Larson, Martin G., additional, van Gilst, Wiek H., additional, Gottdiener, John S., additional, Bertoni, Alain G., additional, and Ho, Jennifer E., additional
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.